What type of study is this?

This is a RCT study (also classified as: Phase 2, Human Clinical Trial).

September 10, 2025Hypertension ResearchOpen Access

Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24

View Full Paper

Ask AI

Bookmark

Baxdrostat significantly lowers systolic blood pressure in patients with uncontrolled hypertension and resistant hypertension.
The primary endpoint is the change in mean seated office systolic blood pressure at Week 12 in different trial populations.
Randomized, multi-national, double-blind, placebo-controlled trials evaluate baxdrostat's efficacy and safety profile.
The trials will provide insights into aldosterone synthase inhibition as a potential novel treatment for hypertension.

No takes yet. Share an insight, caveat, or question.

Phase 3 trials assess baxdrostat's impact on systolic blood pressure in uncontrolled hypertension, highlighting safety and efficacy.

Flack et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark